Aug 20, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
INCY Stock Trading Close to Its 52-Week High: Buy, Sell or Hold?
Incyte hits a fresh 52-week high on strong Jakafi and Opzelura sales, pipeline wins and upbeat investor sentiment.
Aug 20, 2025 • GlobeNewswire
NEUTRAL
Cytokinetics Names Jim Daly to Board of Directors
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated ( Nasdaq: CYTK ) today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025. Mr. Daly brings over 30 years of global biopharmaceutical leadership experience with ...
Aug 20, 2025 • Benzinga
NEUTRAL
Cytokinetics Names Jim Daly to Board of Directors - Cytokinetics ( NASDAQ:CYTK )
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- Cytokinetics, Incorporated CYTK today announced the appointment of James M. Daly to its Board of Directors effective August 19, 2025.
Aug 07, 2025 • Benzinga
NEUTRAL
Knight Therapeutics Reports Second Quarter 2025 Results
Achieved record-high quarterly revenues since inception Increased 2025 financial guidance MONTREAL, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc. GUD ( "Knight" or "the Company" ) , a pan-American ( ex-US ) specialty pharmaceutical company, today reported financial results for its ...
Aug 06, 2025 • Motley Fool
SOMEWHAT-BULLISH
Xencor ( XNCR ) Q2 Revenue Jumps 82%
Xencor ( NASDAQ:XNCR ) , a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company's GAAP revenue of $43.6 million exceeded analyst estimates by $21.0 million and Revenue ( GAAP ) increased ...
Aug 06, 2025 • GlobeNewswire
NEUTRAL
Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer
CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- Actuate Therapeutics, Inc. ( NASDAQ: ACTU ) ( "Actuate" or the "Company" ) , a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the ...